Amoy Diagnostics Co., Ltd.

Shenzhen Stock Exchange 300685.SZ

Amoy Diagnostics Co., Ltd. EBITDA Margin for the year ending December 31, 2023: 33.79%

Amoy Diagnostics Co., Ltd. EBITDA Margin is 33.79% for the year ending December 31, 2023, a -18.84% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Amoy Diagnostics Co., Ltd. EBITDA Margin for the year ending December 31, 2022 was 41.63%, a 31.08% change year over year.
Amoy Diagnostics Co., Ltd. EBITDA Margin for the year ending December 31, 2021 was 31.76%, a 1.07% change year over year.
Amoy Diagnostics Co., Ltd. EBITDA Margin for the year ending December 31, 2020 was 31.42%, a -6.00% change year over year.
Amoy Diagnostics Co., Ltd. EBITDA Margin for the year ending December 31, 2019 was 33.43%, a -9.79% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Shenzhen Stock Exchange: 300685.SZ

Amoy Diagnostics Co., Ltd.

CEO	Ms. Ying Chen
IPO Date	Aug. 3, 2017
Location	China
Headquarters	39 Dingshan Road
Employees	1,119
Sector	Healthcare
Industries Biotechnology

Description

Amoy Diagnostics Co., Ltd., a diagnostic company, focuses on molecular diagnostics for oncology precision medicine in China and internationally. The company offers NGS, real-time PCR, FISH, and extraction assays. Amoy Diagnostics Co., Ltd. was founded in 2008 and is based in Xiamen, China.

Key trends

Past 5 years